BRK-B vs JFR
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is weak, highlighted by a Piotroski F-Score of 3/9, indicating deteriorating operational efficiency and profitability trends. While the company maintains a fortress balance sheet with a Debt/Equity ratio of 0.19 and a Current Ratio of 7.07, the stock is trading at a significant premium to its growth-based intrinsic value of $217.21. Negative YoY revenue and earnings growth, coupled with a bearish technical trend, offset the positive analyst sentiment and long-term historical performance.
JFR exhibits a stable but fragile financial health profile with a Piotroski F-Score of 4/9 and no Altman Z-Score available. While the fund trades at a discount to book value (P/B 0.87) and below its Graham Number ($8.07), these value metrics are overshadowed by a catastrophic collapse in earnings growth (-52.80% YoY). Most critically, the dividend payout ratio of 300% indicates that the 12.56% yield is unsustainable and likely being funded by return of capital rather than earnings. Combined with a 0/100 technical trend and bearish insider activity, the outlook is negative.
Compare Another Pair
Related Comparisons
BRK-B vs JFR: Head-to-Head Comparison
This page compares Berkshire Hathaway Inc. (BRK-B) and Nuveen Floating Rate Income Fund (JFR) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.